Eligibility is selective, with strict BMI, age, comorbidity, and previous-treatment criteria, and some participants receive placebo (a dummy version of the drug)
Climacteric 23 , 532538 (2020)
Studies lasting up to 52 weeks with various GLP-1 medications show no systematic changes in calcitonin concentrations
Tirzepatide (Mounjaro/Zepbound) : If you miss a dose and remember within four days , administer the missed dose
While clinical evidence is still emerging, GLP-1s potential dual ability to reduce the risk of comorbidities and stabilize patients with fewer additional drugs positions them as a cornerstone of modern diabetes care
These expanded studies will test the medication in larger and more diverse populations, assess longer-term outcomes, and provide the data required for regulatory approval submissions to both the FDA and Health Canada